What's known on the subject? and What does the study add?
- Since their discovery aurora kinases have been identified as a potential target in anticancer therapy and currently many aurora-selective small molecule kinase inhibitors are in development. Aurora kinases play an essential role as key mitotic regulators and are frequently overexpressed in prostate cancer. In vivo data in the transgenic mouse prostate carcinoma model revealed tumour regressions of >80% in three out of 16 animals and disease stabilizations in 10 out of 16 animals treated with danusertib. Two phase I dose escalation studies with danusertib in patients with advanced solid tumours were performed, which established two doses and schedules for phase II studies. However, the preliminary data of the available phase II studies with danusertib in solid tumours showed limited activity. Danusertib may yield more activity in the treatment of leukaemias than in solid tumours. Danusertib is generally well tolerated with neutropenia as the main dose limiting toxicity.
- This phase II study determined the efficacy and toxicity of danusertib administered intravenously over two different dosing schedules in patients with metastatic castration-resistant prostate cancer (CRPC) with progressive disease after docetaxel-based treatment. Danusertib showed in vivo antitumour activity in prostate cancer models and clinically relevant disease stabilizations were observed in several patients with solid tumours in phase I studies. However, our study revealed that monotherapy with danusertib, although well tolerated, showed only limited activity in the treatment of patients with CRPC. In view of the new advances in the treatment of patients with CRPC and the negative result of our study it is unlikely that danusertib will be further explored for the treatment of patients with CRPC. Further studies are required to establish specific biomarkers predictive for either response or prolonged disease stabilization to select subsets of patients with CRPC who may benefit from treatment with danusertib.
- To determine the efficacy and toxicity of danusertib (formerly PHA-739358) administered i.v. over two different dosing schedules with equivalent dose intensity in patients with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment.
Patients and Methods
- In this open-label, multicentre phase II trial 88 patients were randomly assigned (1:1 ratio) to receive either danusertib 330 mg/m2 over 6 h i.v. on days 1, 8 and 15 (arm A, n = 43) or 500 mg/m2 over 24 h i.v. on days 1 and 15 (arm B, n = 38), every 4 weeks.
- The primary endpoint chosen for this exploratory study was PSA response rate at 3 months.
- Sixty patients (31/43 in arm A and 29/38 in arm B) were evaluable for the primary endpoint.
- Median progression-free survival was 12 weeks in both arms.
- PSA response occurred in one patient in each arm; best overall response was stable disease in eight (18.6%) and 13 (34.2%) patients in arms A and B, respectively.
- Eleven out of 81 (13.6%) treated patients had stable disease for ≥6 months.
- Danusertib was generally well tolerated; the most common grade 3 and 4 drug-related adverse event was neutropenia which occurred in 37.2% (arm A) and 15.8% (arm B) of the patients.
- Danusertib monotherapy shows minimal efficacy in patients with castration-resistant prostate cancer. Further studies are required to establish specific biomarkers predictive for either response or prolonged disease stabilization.
, . The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52: 154–179
, , et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502–1512
, , et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147–1154
, , et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364: 1995–2005
, , et al. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: results from the phase III AFFIRM study. J Clin Oncol 2012; 30 (Suppl. 5); abstr LBA1
, , et al. Overall survival benefit of radium-223 chloride (Alpharadan) in the treatment of patients with symptomatic bone metastasis in castration-resistant prostate cancer: a phase III randomised trial (ALSYMPCA). European Multidisciplinary Cancer Congress (ECCO-ESMO) 2011; Abstract 1LBA
, . Danusertib (formerly PHA-739358) – a novel combined pan-aurora kinases and third generation Bcr-Abl tyrosine kinase inhibitor. Recent Results Cancer Res 2010; 184: 199–214
, , , , Targeting aurora kinases for the treatment of prostate cancer. Cancer Res 2006; 66: 4996–5002
, , et al. PHA-739358, a potent inhibitor of aurora kinases with a selective target inhibition profile relevant to cancer. Mol Cancer Ther 2007; 6: 3158–3168
, , et al. PHA-739358 Investigator Brochure. Nerviano Medical Sciences document AURA-6202-IB-2. 26 September 2006
, , et al. Prostate cancer in a transgenic mouse. Proc Natl Acad Sci USA 1995; 92: 3439–3443
, , et al. Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors. J Clin Oncol 2009; 27: 5094–6001
, , et al. A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. Clin Cancer Res 2009; 15: 6694–7001
, , et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205–216
, , et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 1999; 17: 3461–3467
, , et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148–1159
National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Adult Cancer Pain. V.1. 2006
Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10: 1–10
, , et al. Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation. Prostate 2006; 15: 326–333
, , et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1: 487–495
, , . Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov 2011; 1: 466–468
, , , . Uncommon cancers of the prostate. In D Raghavan et al. ed, Textbook of Uncommon Cancers, 4th edn. Chichester: Wiley, 2012: Chapter 9; Section 1
, , et al. Challenges in recognizing treatment related neuroendocrine prostate cancer. J Clin Oncol 2012 (in press)
, , et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 516–521
Response criteria in prostatic carcinoma. Semin Oncol 1999; 26: 174–184
, , et al. A phase II study of sorafenib in patients with chemo-naive castration-resistant prostate cancer. Ann Oncol 2008; 19: 746–751
, , et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin Cancer Res 2008; 14: 209–214